Mer­ck crush­es Keynote-407 study in front­line lung can­cer, hit­ting co-pri­maries and set­ting up an­oth­er quick OK

Con­tin­u­ing its march to the to­tal dom­i­na­tion of front­line lung can­cer treat­ment, Mer­ck $MRK this morn­ing an­nounced that its Phase III Keynote-407 study hit both the over­all sur­vival as well as the pro­gres­sion-free sur­vival goal posts they were aim­ing at.

Re­searchers test­ed a com­bi­na­tion of Mer­ck’s star PD-1 drug Keytru­da in the front­line set­ting for metasta­t­ic squa­mous non-small cell lung can­cer. They’re hold­ing the num­bers back for AS­CO, but the news now adds fu­el to Mer­ck’s cam­paign to over­take Bris­tol-My­ers Squibb as the num­ber one PD-1/L1 man­u­fac­tur­er by sales rev­enue.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER